BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth
Investment Will Provide BioAgilytix with Additional Resources to Invest in Core Business and Drive Growth.
BioAgilytix Closes Acquisition of Australia-based 360biolabs®
Highly complementary transaction adds virology, immunology and LC-MS/MS small molecule expertise to BioAgilytix, a global leader in bioanalytical services in biologics drug development.
We are excited to announce the opening of our new specialty lab in Brisbane
Continuing to exceed our client’s needs, the opening of our Brisbane laboratory enables 360biolabs to further support clinical trials in the north-east region of Australia.
BioAgilytix to purchase Australia based 360biolabs®
Highly complementary transaction will strengthen company’s ability to support bioanalytical services across all stages, development capabilities and geographies.